{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:16:35Z","timestamp":1793506595901,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["12702"],"award-info":[{"award-number":["12702"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011010","name":"European SocieTy for Radiotherapy and Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.radonc.2025.110910","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:28:30Z","timestamp":1746055710000},"page":"110910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy"],"prefix":"10.1016","volume":"208","author":[{"given":"Evert S.M.","family":"van Aken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharti","family":"Devnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Martins-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie A.M.","family":"Marijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Muoio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Kroeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet Kumar","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsela","family":"Prelaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"O\u2019Cathail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110910_b0005","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.radonc.2025.110910_b0015","first-page":"S3","article-title":"Hormonal therapy in prostate cancer: historical approaches","volume":"6","author":"Crawford","year":"2004","journal-title":"Revista de Urologa"},{"key":"10.1016\/j.radonc.2025.110910_b0020","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.mce.2013.08.001","article-title":"Breast cancer: current and future endocrine therapies","volume":"382","author":"Palmieri","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.radonc.2025.110910_b0025","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.annonc.2021.04.003","article-title":"Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020","volume":"32","author":"Haslam","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.radonc.2025.110910_b0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.radonc.2025.110910_b0040","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.radonc.2025.110910_b0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JGO.2015.001545","article-title":"Global Access to radiotherapy services: have we made progress during the past decade?","volume":"2","author":"Yap","year":"2016","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0050","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent Developments in Radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110910_b0055","doi-asserted-by":"crossref","unstructured":"De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. Radiotherapy toxicity. Nat Rev Dis Primers. 2019;5:13. https:\/\/doi.org\/10.1038\/s41572-019-0064-5.","DOI":"10.1038\/s41572-019-0064-5"},{"key":"10.1016\/j.radonc.2025.110910_b0060","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.110910_b0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0070","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cncr.22555","article-title":"A review of hypofractionated palliative radiotherapy","volume":"109","author":"Lutz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0075","first-page":"93","article-title":"Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: dutch survey on current practice, knowledge and challenges. Clin Transl","volume":"33","author":"van Aken","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8518","article-title":"Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): results from a multi-center phase II trial","volume":"42","author":"Rashdan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2025.110910_b0090","doi-asserted-by":"crossref","unstructured":"van Aken ESM, Beeker A, Houtenbos I, Pos FJ, Linn SC, Elkhuizen PHM, de Jong MC. Unexpected toxicity of CDK4\/6 inhibitor palbociclib and radiotherapy. Cancer Rep (Hoboken). 2021:e1470. https:\/\/doi.org\/10.1002\/cnr2.1470.","DOI":"10.1002\/cnr2.1470"},{"key":"10.1016\/j.radonc.2025.110910_b0095","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-18-2466","article-title":"Clinical development of novel drug-radiotherapy combinations","volume":"25","author":"Ahmad","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0100","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrclinonc.2016.79","article-title":"Clinical development of new drug-radiotherapy combinations","volume":"13","author":"Sharma","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1745-6215-13-138","article-title":"Drug safety assessment in clinical trials: methodological challenges and opportunities","volume":"13","author":"Singh","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.radonc.2025.110910_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030690","article-title":"Safety and Feasibility of Radiation Therapy Combined with CDK 4\/6 Inhibitors in the Management of Advanced Breast Cancer","volume":"15","author":"Kubeczko","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110910_b0115","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and Pharmacologic Study of olaparib in combination with high-dose radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer","volume":"27","author":"de Haan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial","author":"Loap","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/bjc.2017.489","article-title":"Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients","volume":"118","author":"Hecht","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0130","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194780","article-title":"Continued versus Interrupted Targeted Therapy during Metastasis-Directed stereotactic radiotherapy: a retrospective multi-center safety and efficacy analysis","volume":"13","author":"Kroeze","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110910_b0140","doi-asserted-by":"crossref","unstructured":"Harding JJ, Barker CA, Carvajal RD, Wolchok JD, Chapman PB, Lacouture ME. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol. 2014;32:e54-6. DOI: 10.1200\/JCO.2013.49.3528.","DOI":"10.1200\/JCO.2013.49.3528"},{"key":"10.1016\/j.radonc.2025.110910_b0145","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1200\/JCO.2013.49.0565","article-title":"Acute Radiation Skin Toxicity Associated With BRAF Inhibitors","volume":"34","author":"Pulvirenti","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.radonc.2025.110910_b0155","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/JTO.0b013e318257fc1d","article-title":"Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib","volume":"7","author":"Pop","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0160","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0165","article-title":"Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma","volume":"27","author":"Amirault","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.radonc.2025.110910_b0170","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","article-title":"International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: european society for radiotherapy and oncology (ESTRO)-endorsed recommendations","volume":"25","author":"Meattini","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0175","doi-asserted-by":"crossref","unstructured":"Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023;24:e121-e32. https:\/\/doi.org\/10.1016\/S1470-2045(22)00752-5.","DOI":"10.1016\/S1470-2045(22)00752-5"},{"key":"10.1016\/j.radonc.2025.110910_b0180","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/COC.0000000000000501","article-title":"Concurrent radiation and immunotherapy: survey of practice patterns in the united states","volume":"42","author":"Amin","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0185","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1038\/s41598-021-86863-2","article-title":"Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade","volume":"11","author":"Kraus","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.110910_b0190","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clon.2013.06.007","article-title":"Biological consequences of radiation-induced DNA damage: relevance to radiotherapy","volume":"25","author":"Lomax","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.110910_b0195","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.radonc.2025.110910_b0200","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3109\/09553000903261263","article-title":"Cellular radiosensitivity: how much better do we understand it?","volume":"85","author":"Jeggo","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2025.110910_b0205","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1021\/jz4000998","article-title":"Radiation Damage to DNA: The Indirect Effect of Low Energy Electrons","volume":"4","author":"Alizadeh","year":"2013","journal-title":"J Phys Chem Lett"},{"key":"10.1016\/j.radonc.2025.110910_b0210","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/nar\/gkp237","article-title":"Cellular responses to DNA double-strand breaks after low-dose gamma-irradiation","volume":"37","author":"Asaithamby","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.radonc.2025.110910_b0215","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/09553000601170469","article-title":"Kinetics and dose-response of residual 53BP1\/gamma-H2AX foci: co-localization, relationship with DSB repair and clonogenic survival","volume":"83","author":"Markova","year":"2007","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2025.110910_b0220","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1667\/RR1165.1","article-title":"Repair of HZE-particle-induced DNA double-strand breaks in normal human fibroblasts","volume":"169","author":"Asaithamby","year":"2008","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2025.110910_b0225","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1083\/jcb.151.7.1381","article-title":"p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks","volume":"151","author":"Schultz","year":"2000","journal-title":"J Cell Biol"},{"key":"10.1016\/j.radonc.2025.110910_b0230","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1073\/pnas.0830918100","article-title":"Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses","volume":"100","author":"Rothkamm","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.radonc.2025.110910_b0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.radonc.2025.110910_b0240","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1073\/pnas.131009198","article-title":"Single-strand interruptions in replicating chromosomes cause double-strand breaks","volume":"98","author":"Kuzminov","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.radonc.2025.110910_b0245","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0250","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.radonc.2025.110910_b0255","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clon.2016.01.035","article-title":"Science in focus: combining radiotherapy with inhibitors of the DNA Damage Response","volume":"28","author":"Chalmers","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.110910_b0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/mutage\/gei063","article-title":"DNA damage checkpoints in mammals","volume":"21","author":"Niida","year":"2006","journal-title":"Mutagenesis"},{"key":"10.1016\/j.radonc.2025.110910_b0265","doi-asserted-by":"crossref","DOI":"10.1093\/jrr\/rrx074","article-title":"Radiation-induced unrepairable DSBs: their role in the late effects of radiation and possible applications to biodosimetry","volume":"59","author":"Noda","year":"2018","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2025.110910_b0270","article-title":"Quantification of radiation-induced DNA double strand break repair foci to evaluate and predict biological responses to ionizing radiation. NAR","volume":"3","author":"Penninckx","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0275","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semradonc.2010.05.004","article-title":"Use of gammaH2AX and other biomarkers of double-strand breaks during radiotherapy","volume":"20","author":"Sak","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2021.108388","article-title":"Evaluation of DNA double-strand break repair capacity in human cells: Critical overview of current functional methods","volume":"788","author":"Tatin","year":"2021","journal-title":"Mutat Res Rev Mutat Res"},{"key":"10.1016\/j.radonc.2025.110910_b0285","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-016-0433-9","article-title":"Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword","volume":"35","author":"Visconti","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2021.09.008","article-title":"Targeting the ATM kinase to enhance the efficacy of radiotherapy and outcomes for cancer patients","volume":"32","author":"Garcia","year":"2022","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0300","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41416-023-02542-1","article-title":"CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method","volume":"130","author":"Javed","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.radonc.2025.110910_b0310","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2021.02.009","article-title":"A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)","volume":"22","author":"Argiris","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0315","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2021.06.028","article-title":"Veliparib in combination with carboplatin\/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer","volume":"159","author":"Kozono","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11060-016-2275-x","article-title":"Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study","volume":"131","author":"Chabot","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2025.110910_b0325","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","article-title":"Concurrent Veliparib With Chest Wall and Nodal radiotherapy in patients with inflammatory or locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study","volume":"36","author":"Jagsi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0330","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-18-0467","article-title":"Final Report of a Phase I Trial of Olaparib with cetuximab and radiation for heavy smoker patients with Locally Advanced Head and Neck Cancer","volume":"24","author":"Karam","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0335","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc1412","article-title":"Pathways of apoptotic and non-apoptotic death in tumour cells","volume":"4","author":"Okada","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0340","first-page":"931","article-title":"Using computerized video time lapse for quantifying cell death of X-irradiated Rat Embryo Cells Transfected with c-myc or c-Ha-ras1","volume":"59","author":"Forrester","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0345","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature24050","article-title":"Cytoplasmic chromatin triggers inflammation in senescence and cancer","volume":"550","author":"Dou","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2025.110910_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.645593","article-title":"Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype","volume":"9","author":"Kumari","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.radonc.2025.110910_b0355","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.molcel.2009.09.021","article-title":"Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence","volume":"36","author":"Adams","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.radonc.2025.110910_b0360","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3389\/fphys.2019.01523","article-title":"Where metabolism meets senescence: focus on endothelial cells","volume":"10","author":"Sabbatinelli","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.radonc.2025.110910_b0365","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rpor.2014.08.004","article-title":"Bystander effects and radiotherapy","volume":"20","author":"Marin","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.radonc.2025.110910_b0370","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nature23284","article-title":"Cysteine protease cathepsin B mediates radiation-induced bystander effects","volume":"547","author":"Peng","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2025.110910_b0375","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1667\/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2","article-title":"Radiation-Induced Bystander Effects: Past History and Future Directions","volume":"155","author":"Mothersill","year":"2001","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2025.110910_b0380","doi-asserted-by":"crossref","DOI":"10.2307\/3579436","article-title":"Spatial and Temporal patterns of expression of epidermal growth factor, transforming growth factor alpha and transforming growth factor Beta 1-3 and Their Receptors in Mouse Jejunum after Radiation Treatment","volume":"147","author":"Ruifrok","year":"1997","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2025.110910_b0385","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0167-8140(01)00429-7","article-title":"Consequential late effects in normal tissues","volume":"61","author":"Dorr","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0390","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2015.01.019","article-title":"Acute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia","volume":"115","author":"van der Laan","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0395","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0360-3016(98)00410-6","article-title":"Immediate side effects of stereotactic radiotherapy and radiosurgery","volume":"43","author":"Werner-Wasik","year":"1999","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110910_b0400","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/156652409787847164","article-title":"Molecular aspects of intestinal radiation-induced fibrosis","volume":"9","author":"Gervaz","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.radonc.2025.110910_b0405","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tranon.2018.09.009","article-title":"Advances in Molecular Mechanisms and Treatment of Radiation-Induced Pulmonary Fibrosis","volume":"12","author":"Chen","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0410","doi-asserted-by":"crossref","first-page":"22099","DOI":"10.1038\/s41598-023-43202-x","article-title":"Long-term findings of rectal endoscopy and rectal bleeding after moderately hypofractionated, intensity-modulated radiotherapy for prostate cancer","volume":"13","author":"Bae","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.110910_b0415","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.radonc.2021.01.026","article-title":"Risk of ischaemic cerebrovascular events in head and neck cancer patients is associated with carotid artery radiation dose","volume":"157","author":"van Aken","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0420","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005633","article-title":"Long\u2010Term Cardiovascular Risk After radiotherapy in women with breast cancer","volume":"6","author":"Cheng","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.radonc.2025.110910_b0425","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.radonc.2025.110910_b0430","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2025.110910_b0440","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2014.215","article-title":"Oncogenic KRAS signalling in pancreatic cancer","volume":"111","author":"Eser","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0445","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","article-title":"The mTOR signalling pathway in human cancer","volume":"13","author":"Populo","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.radonc.2025.110910_b0450","doi-asserted-by":"crossref","unstructured":"Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007;4:1669-79; discussion 80. https:\/\/doi.org\/10.1371\/journal.pmed.0040315.","DOI":"10.1371\/journal.pmed.0040315"},{"key":"10.1016\/j.radonc.2025.110910_b0455","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.radonc.2025.110910_b0460","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1124\/mol.107.043794","article-title":"Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells","volume":"73","author":"Kumar","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.radonc.2025.110910_b0465","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.radonc.2025.110910_b0470","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0475","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395996","article-title":"PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation","volume":"7","author":"Morisada","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2025.110910_b0480","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0485","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2025.110910_b0490","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0495","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110910_b0500","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/stem.3391","article-title":"Radiotherapy and the immune system: More than just immune suppression","volume":"39","author":"R\u00fcckert","year":"2021","journal-title":"Stem Cells"},{"key":"10.1016\/j.radonc.2025.110910_b0505","doi-asserted-by":"crossref","first-page":"16223","DOI":"10.1038\/s41598-020-72876-w","article-title":"Radionecrosis and cellular changes in small volume stereotactic brain radiosurgery in a porcine model","volume":"10","author":"Zaer","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.110910_b0510","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jrr\/rru017","article-title":"Inflammation as well as angiogenesis may participate in the pathophysiology of brain radiation necrosis","volume":"55","author":"Yoritsune","year":"2014","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2025.110910_b0515","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11912-019-0818-y","article-title":"Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities","volume":"21","author":"Ali","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.radonc.2025.110910_b0520","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/ni.3236","article-title":"Subversion of anticancer immunosurveillance by radiotherapy","volume":"16","author":"Zitvogel","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.radonc.2025.110910_b0525","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1201500","article-title":"A review on lymphocyte radiosensitivity and its impact on radiotherapy","volume":"13","author":"Paganetti","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110041","article-title":"Modeling frameworks for radiation induced lymphopenia: A critical review","volume":"190","author":"Cella","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0535","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246193","article-title":"Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110910_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110030","article-title":"The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC","volume":"190","author":"Friedes","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0545","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: Immune Checkpoint Inhibitors","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2025.110910_b0550","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.radonc.2025.110910_b0555","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.radonc.2025.110910_b0560","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00262-021-03002-6","article-title":"Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer","volume":"71","author":"Hoffmann","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.radonc.2025.110910_b0565","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2021.02.007","article-title":"Mechanisms of radiation-induced endothelium damage: Emerging models and technologies","volume":"158","author":"Wijerathne","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0570","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.drup.2012.04.002","article-title":"Combining angiogenesis inhibition and radiotherapy: a double-edged sword","volume":"15","author":"Kleibeuker","year":"2012","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.radonc.2025.110910_b0575","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccr.2007.11.032","article-title":"Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells","volume":"13","author":"Ahn","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2025.110910_b0580","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bjc.6603637","article-title":"The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes","volume":"96","author":"Giotopoulos","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0585","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-06-2441","article-title":"Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization","volume":"13","author":"Dings","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110910_b0590","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.742215","article-title":"Hypoxia in Solid Tumors: How Low Oxygenation Impacts the \u201cSix Rs\u201d of Radiotherapy","volume":"12","author":"Rakotomalala","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.radonc.2025.110910_b0595","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1667\/RR13959.1","article-title":"Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity","volume":"183","author":"Liu","year":"2015","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2025.110910_b0600","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41420-020-00311-0","article-title":"Inside the hypoxic tumour: reprogramming of the DDR and radioresistance","volume":"6","author":"Begg","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.radonc.2025.110910_b0605","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000421-199808000-00008","article-title":"The Oxygen Fixation Hypothesis: A Reevaluation","volume":"21","author":"Ewing","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0610","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijrobp.2020.03.003","article-title":"Ionizing Radiation Regulates Vascular Endothelial Growth Factor-A Transcription in Cultured Human Vascular Endothelial Cells Via the PERK\/eIF2alpha\/ATF4 Pathway","volume":"107","author":"Kim","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110910_b0615","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b5349","article-title":"Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950-2003","volume":"340","author":"Shimizu","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2025.110910_b0620","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.22452","article-title":"Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer","volume":"109","author":"Jagsi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0625","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijrobp.2018.10.025","article-title":"Radiation Dose-Response for Risk of myocardial infarction in breast cancer survivors","volume":"103","author":"Jacobse","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110910_b0630","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.2016.69.8480","article-title":"Validation and Modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures","volume":"35","author":"van den Bogaard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0635","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation Dose-Response Relationship for risk of coronary heart disease in survivors of hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0640","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00066-018-1304-4","article-title":"Radiation-induced carotid artery lesions","volume":"194","author":"Fernandez-Alvarez","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2025.110910_b0645","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-7120-8-8","article-title":"Effects of external irradiation of the neck region on intima media thickness of the common carotid artery","volume":"8","author":"Gianicolo","year":"2010","journal-title":"Cardiovasc Ultrasound"},{"key":"10.1016\/j.radonc.2025.110910_b0650","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.radonc.2013.08.009","article-title":"Radiation-induced carotid artery atherosclerosis","volume":"110","author":"Gujral","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0655","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jcu.21971","article-title":"Sonographic assessment of acute changes in plaque size and echogenicity and in intima-media thickness of carotid arteries after neck radiation therapy","volume":"40","author":"Toprak","year":"2012","journal-title":"J Clin Ultrasound"},{"key":"10.1016\/j.radonc.2025.110910_b0660","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.radonc.2015.11.025","article-title":"Carotid intima-medial thickness as a marker of radiation-induced carotid atherosclerosis","volume":"118","author":"Gujral","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0665","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199901073400103","article-title":"Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group","volume":"340","author":"O'Leary","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110910_b0670","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000047771","article-title":"Sonographic characterisation of radiation-induced carotid artery stenosis","volume":"13","author":"Lam","year":"2002","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.radonc.2025.110910_b0675","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1024\/0301-1526\/a000403","article-title":"Carotid artery disease after head and neck radiotherapy","volume":"44","author":"Thalhammer","year":"2015","journal-title":"Vasa"},{"key":"10.1016\/j.radonc.2025.110910_b0680","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11912-012-0237-9","article-title":"The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients","volume":"14","author":"Sonpavde","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.radonc.2025.110910_b0685","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/jth.15354","article-title":"Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy","volume":"19","author":"Watson","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.radonc.2025.110910_b0690","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0695","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jtho.2023.04.007","article-title":"Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents","volume":"18","author":"Lau","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0700","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2019.0205","article-title":"Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0705","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/annonc\/mdu148","article-title":"Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF","volume":"25","author":"Chauffert","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0710","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2025.110910_b0715","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume":"87","author":"Barney","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110910_b0720","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1477-7819-10-167","article-title":"Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma","volume":"10","author":"Inoue","year":"2012","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0725","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bjmsu.2009.11.003","article-title":"Small bowel perforation in a patient with metastatic renal cancer treated with radiotherapy and Sunitinib","volume":"3","author":"Kwan","year":"2010","journal-title":"British Journal of Medical and Surgical Urology"},{"key":"10.1016\/j.radonc.2025.110910_b0730","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","article-title":"Bowel perforation after radiotherapy in a patient receiving sorafenib","volume":"26","author":"Peters","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0735","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jtho.2018.08.2031","article-title":"Tracheoesophageal Fistula in a Patient with Advanced Non-Small Cell Lung Cancer Who Received Chemoradiotherapy and Ramucirumab","volume":"14","author":"Lee","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0740","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00595-012-0475-3","article-title":"Gastro-pleuro-pericardial fistula following combined radiation and chemotherapy for lung metastases from renal cell carcinoma: report of a case","volume":"43","author":"Neri","year":"2013","journal-title":"Surg Today"},{"key":"10.1016\/j.radonc.2025.110910_b0745","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2014.05.011","article-title":"Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity","volume":"90","author":"Stephans","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110910_b0750","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1345\/aph.1M469","article-title":"Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy","volume":"44","author":"Basille","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.radonc.2025.110910_b0755","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s00066-017-1178-x","article-title":"Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy","volume":"193","author":"Sturdza","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2025.110910_b0760","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bcr.08.2010.3284","article-title":"Tracheal fistula associated with bevacizumab 20 months after mediastinal radiation","volume":"2010","author":"Yamada","year":"2010","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.radonc.2025.110910_b0765","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110910_b0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"10.1016\/j.radonc.2025.110910_b0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2025.110910_b0780","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clon.2022.02.009","article-title":"How Low Can You Go? The Radiobiology of Hypofractionation","volume":"34","author":"Brand","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.110910_b0785","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clon.2015.02.001","article-title":"The radiobiology of hypofractionation","volume":"27","author":"Nahum","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.110910_b0790","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/02841869709109220","article-title":"Specification of the dose to organs at risk in external beam radiotherapy","volume":"36","author":"Dale","year":"1997","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0795","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of lorlatinib: cumulative incidences of CNS and Non-CNS progression with lorlatinib in patients with previously Treated ALK-Positive Non-Small-Cell Lung Cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0800","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood\u2013brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.radonc.2025.110910_b0805","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2025.110910_b0810","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1074\/mcp.M500279-MCP200","article-title":"A human protein atlas for normal and cancer tissues based on antibody proteomics","volume":"4","author":"Uhlen","year":"2005","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.radonc.2025.110910_b0815","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.radonc.2025.110910_b0820","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-019-03806-5","article-title":"Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report : Radiation\/systemic drug combo in metastatic melanoma","volume":"83","author":"Couty","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.radonc.2025.110910_b0825","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/CAD.0000000000000349","article-title":"Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report","volume":"27","author":"Langrand-Escure","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.radonc.2025.110910_b0830","unstructured":"Hallare J GV. Half Life. StatPearls [Internet], Treasure Island (FL): StatPearls Publishing. Updated 2023 Jun 20."},{"key":"10.1016\/j.radonc.2025.110910_b0835","series-title":"Applied Biopharmaceutics & Pharmacokinetics, 7e","author":"Shargel","year":"2016"},{"key":"10.1016\/j.radonc.2025.110910_b0840","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1124\/dmd.119.086744","article-title":"Drug Concentration asymmetry in tissues and plasma for Small Molecule-Related Therapeutic Modalities","volume":"47","author":"Zhang","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.radonc.2025.110910_b0845","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ddr.10346","article-title":"The clinical pharmacology of therapeutic monoclonal antibodies","volume":"61","author":"Roskos","year":"2004","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.radonc.2025.110910_b0850","doi-asserted-by":"crossref","DOI":"10.1177\/1178223418823238","article-title":"Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced\/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy","volume":"13","author":"Bui","year":"2019","journal-title":"Breast Cancer (Auckl)"},{"key":"10.1016\/j.radonc.2025.110910_b0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110115","article-title":"Shared decision making with breast cancer patients - does it work? Results of the cluster-randomized, multicenter DBCG RT SDM trial","volume":"193","author":"Sondergaard","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0860","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0167-8140(99)00151-6","article-title":"Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer","volume":"53","author":"Bentzen","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0865","first-page":"1719","article-title":"Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study","volume":"71","author":"Bilger","year":"2022","journal-title":"CancerImmunology, Immunotherapy"},{"key":"10.1016\/j.radonc.2025.110910_b0870","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20140800","article-title":"Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer","volume":"88","author":"Pernin","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.110910_b0875","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdw204","article-title":"Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer","volume":"27","author":"Argiris","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.110910_b0880","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2017.11.005","article-title":"Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I\/II trial (SAKK 41\/08)","volume":"89","author":"von Moos","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:41:01Z","timestamp":1762256461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025002051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":176,"alternative-id":["S0167814025002051"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110910","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESMO-ESTRO framework for assessing the interactions and safety of combining radiotherapy with targeted cancer therapies or immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110910"}}